Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.

Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Marin F, Krege JH

Bone18 Jul 2018Cited by 71 (Europe PMC)

PMID30021126DOI10.1016/j.bone.2018.07.013PepBankPUB-30021126

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, clinical vertebral fracture rates were lower after 6 months than during the initial treatment period.
In plain wordsIn osteoporosis patients, later teriparatide treatment was linked to fewer clinical vertebral fractures than the initial treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseClinical vertebral fracture rate
Study
n = 8,828
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Measurements
CVF rate reduction
62%
>6 months versus 0 to 6 months
Source sentences
Summary
Overall, CVF, NVF, clinical fracture, and hip fracture rates decreased by 62%, 43%, 50%, and 56%, respectively (all p < .005) for >6 months versus 0 to 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112601
02HumanObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, nonvertebral fracture rates were lower after 6 months than during the initial treatment period.
In plain wordsIn osteoporosis patients, later teriparatide treatment was linked to fewer nonvertebral fractures than the initial treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fracture rate
Study
n = 8,828
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Measurements
NVF rate reduction
43%
>6 months versus 0 to 6 months
Source sentences
Summary
Overall, CVF, NVF, clinical fracture, and hip fracture rates decreased by 62%, 43%, 50%, and 56%, respectively (all p < .005) for >6 months versus 0 to 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112602
03HumanObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, clinical fracture rates were lower after 6 months than during the initial treatment period.
In plain wordsIn osteoporosis patients, later teriparatide treatment was linked to fewer clinical fractures than the initial treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseClinical fracture rate
Study
n = 8,828
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Measurements
Clinical fracture rate reduction
50%
>6 months versus 0 to 6 months
Source sentences
Summary
Overall, CVF, NVF, clinical fracture, and hip fracture rates decreased by 62%, 43%, 50%, and 56%, respectively (all p < .005) for >6 months versus 0 to 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112603
04HumanObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, hip fracture rates were lower after 6 months than during the initial treatment period.
In plain wordsIn osteoporosis patients, later teriparatide treatment was linked to fewer hip fractures than the initial treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseHip fracture rate
Study
n = 8,828
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Measurements
Hip fracture rate reduction
56%
>6 months versus 0 to 6 months
Source sentences
Summary
Overall, CVF, NVF, clinical fracture, and hip fracture rates decreased by 62%, 43%, 50%, and 56%, respectively (all p < .005) for >6 months versus 0 to 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112604
05HumanObservational studyEfficacy outcome
In men receiving teriparatide, nonvertebral fracture rates did not decrease significantly after 6 months versus the initial treatment period.
In plain wordsIn men, later teriparatide treatment was not linked to significantly fewer nonvertebral fractures than the initial treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonvertebral fracture rate in men
Study
n = 710
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Source sentences
Summary
Subgroup analyses all showed significantly decreased rates after >6 months except for NVF reduction in males (n = 710, fracture rate low during months 0 to 6) and in patients using glucocorticoids, and CVF in patients with prior hip fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112605
06HumanObservational studyEfficacy outcome
In glucocorticoid users receiving teriparatide, nonvertebral fracture rates did not decrease significantly after 6 months versus the initial treatment period.
In plain wordsIn glucocorticoid users, later teriparatide treatment was not linked to significantly fewer nonvertebral fractures than the initial treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonvertebral fracture rate in glucocorticoid users
Study
n: not reported in source
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Source sentences
Summary
Subgroup analyses all showed significantly decreased rates after >6 months except for NVF reduction in males (n = 710, fracture rate low during months 0 to 6) and in patients using glucocorticoids, and CVF in patients with prior hip fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112606
07HumanObservational studyEfficacy outcome
In teriparatide users with prior hip fracture, clinical vertebral fracture rates did not decrease significantly after 6 months versus initial treatment.
In plain wordsWith prior hip fracture, later teriparatide treatment was not linked to significantly fewer clinical vertebral fractures than initial treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeClinical vertebral fracture rate with prior hip fracture
Study
n: not reported in source
Comparator
Treatment months 0 to 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · up to 24 monthsAs given in this study (human).
Source sentences
Summary
Subgroup analyses all showed significantly decreased rates after >6 months except for NVF reduction in males (n = 710, fracture rate low during months 0 to 6) and in patients using glucocorticoids, and CVF in patients with prior hip fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
Report a problemFND-3002112607

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, the reduction in clinical vertebral fracture rate over time was reported to be better in patients younger than 75 than in older patients (interaction p = .074).
In plain wordsAmong teriparatide users, younger patients had a better vertebral fracture response over time than older patients, with an age-difference p value of .074.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableAge-related clinical vertebral fracture response
Study
n: not reported in source
Comparator
Age ≥75 years
Outcome group
Bone and joint · Musculoskeletal
Measurements
Age interaction p (clinical vertebral fracture)
0.074
age <75 versus age >=75 years
Source sentences
Summary
The effects of teriparatide on CVF, NVF, and clinical fractures over time were statistically consistent in all subgroups except age for CVF (p = .074, patients <75 years of age responded better), and diabetes for clinical fractures (p = .046, patients with diabetes responded better), although all of…
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3002112608
09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In a non-controlled integrated analysis of osteoporosis patients on teriparatide, the reduction in clinical fracture rates over time differed by diabetes status, with patients with diabetes responding better (p = .046), although all subgroups had significant reductions.
In plain wordsAmong patients on teriparatide, those with diabetes were linked to a better fracture response over time than those without; both groups improved.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedDiabetes-related clinical fracture response
Study
n: not reported in source
Comparator
Without diabetes
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The effects of teriparatide on CVF, NVF, and clinical fractures over time were statistically consistent in all subgroups except age for CVF (p = .074, patients <75 years of age responded better), and diabetes for clinical fractures (p = .046, patients with diabetes responded better), although all of…
3 context sentences(design, population, supporting numbers)
Summary · context
We assessed fracture outcomes in subgroups of osteoporosis patients from 4 real-world teriparatide observational studies.
Summary · context
Patients received teriparatide 20 μg/day for up to 24 months.
Summary · context
Fracture rates were compared between 0 to 6 months versus >6 months using a piecewise exponential model for first fracture.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3002112609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.